source
- Inhibrx reports 9.6-month median PFS for OX40 agonist combo in phase 2 head-neck cancer trialInhibrx Biosciences presented updated data from its phase‑2 HexAgon study of the hexavalent OX40 agonist INBRX‑106 combined with Merck’s Keytruda in patients with untreated metastatic or unresectab…
- Six AI agents run on a deskside system to deliver on-premises clinical decision supportHealthcare organizations have long struggled to balance the promise of artificial intelligence with the need to keep patient data secure. Cloud‑based large language models can provide powerful clin…